Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125,125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort.
Song Y, Hu C, Xie Z, Wu L, Zhu Z, Rao C, Liu L, Chen Y, Liang N, Chen J, Hu C, Yang N, Hu J, Zhao W, Tong G, Dong X, Zheng D, Jin M, Chen J, Huang M, He Y, Rosell R, Lippi G, Mino-Kenudson M, Han-Zhang H, Mao X, Zhang L, Liu H, Field JK, Chuai S, Ye J, Han Y, Lu S; Written on behalf of AME Lung Cancer Collaborative Group. Song Y, et al. Among authors: zhang l. Transl Lung Cancer Res. 2020 Apr;9(2):269-279. doi: 10.21037/tlcr.2020.03.17. Transl Lung Cancer Res. 2020. PMID: 32420066 Free PMC article.
Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib.
Su Y, Long X, Song Y, Chen P, Li S, Yang H, Wu P, Wang Y, Bing Z, Cao Z, Cao L, Wu Y, Zhang Z, Liu J, Li B, Xiang J, Ma K, Zhang T, Zhang L, Mao X, Liu H, Xing P, Liang N. Su Y, et al. Among authors: zhang l, zhang t, zhang z. Target Oncol. 2019 Apr;14(2):159-168. doi: 10.1007/s11523-019-00631-x. Target Oncol. 2019. PMID: 30895431
EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma.
Xiang C, Zhang W, Xiong LW, Cai XW, Teng HH, Zhao RY, Shang ZX, Han-Zhang H, Zhang L, Yan L, Chen ZQ, Han YC. Xiang C, et al. Among authors: zhang l, zhang w. JTO Clin Res Rep. 2021 May 18;2(7):100185. doi: 10.1016/j.jtocrr.2021.100185. eCollection 2021 Jul. JTO Clin Res Rep. 2021. PMID: 34590035 Free PMC article.
125,125 results
You have reached the last available page of results. Please see the User Guide for more information.